A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807949 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

563

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Interventions

DRUG: Placebo
DRUG: Lumacaftor Plus Ivacaftor Combination
DRUG: Ivacaftor

Sponsor

Vertex Pharmaceuticals Incorporated